Clinical trial of sevelamium carbonate in the treatment of maintenance hemodialysis patients
10.13699/j.cnki.1001-6821.2024.08.011
- VernacularTitle:碳酸司维拉姆治疗维持性血液透析患者的临床研究
- Author:
Wei YANG
1
;
Li CHENG
;
Fang CHEN
;
Hua-Nan ZHAO
Author Information
1. 亳州市中医院肾病科,安徽亳州 236800
- Keywords:
sevelamer carbonate;
maintenance hemodialysis;
serum phosphorus;
parathyroid function
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(8):1140-1144
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of sevelamer carbonate on blood phosphorus,vascular calcification,and parathyroid function in maintenance hemodialysis(MHD)patients.Methods MHD patients were selected as the research subjects and divided into treatment group and control group according to the treatment plan using a cohort method.The control group was given calcium carbonate chewable tablets orally at a dose of 1.25 g,bid,while the treatment group was given sevelamer carbonate tablets orally at a dose of 0.8 g,tid;the duration of treatment for both groups was 6 months.The clinical efficacy,blood phosphorus,blood calcium,coronary artery calcification score,parathyroid function[intact parathyroid hormone(iPTH),parathyroid volume],and levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]were compared between the two groups,and the occurrence of adverse drug reactions was recorded.Results The total effective rates of the treatment group and the control group were 92.45％(49 cases/53 cases)and 77.55％(38 cases/49 cases)respectively,showing statistically significant difference(P＜0.05).After 6 months of treatment,the blood phosphorus levels of the treatment group and the control group were(1.63±0.31)and(2.07±0.36)mmol·L-1,respectively;blood calcium levels were(2.31±0.17)and(2.47±0.12)mmol·L-1,respectively;coronary artery calcification scores were 71.81±15.45 and 86.03±17.49,respectively;iPTH expression levels were(223.59±64.85)and(304.25±74.61)pg·mL-1,respectively;parathyroid volumes were(1.03±0.26)and(1.17±0.21)cm3,respectively;CRP expression levels were(5.12±1.35)and(6.59±1.66)mg·L-1,respectively;IL-6 expression levels were(16.32±2.81)and(19.84±3.62)ng·L-1,respectively;TNF-αexpression levels were(18.54±3.88)and(22.69±4.89)ng·L-1,respectively.The differences in the above indicators between the treatment group and the control group were all statistically significant(all P＜0.05).The total incidence of adverse drug reactions in the treatment group and the control group were 9.43％(5 cases/53 cases)and 6.12％(3 cases/49 cases),respectively,with no statistically significant difference(P＞0.05).Conclusion Sevelamer carbonate can reduce blood phosphorus levels in MHD patients,has minimal effect on blood calcium concentration,improves parathyroid function in patients,delays vascular calcification,and has good clinical application effects.
